How Many Tesaro, Inc. (NASDAQ:TSRO)’s Analysts Are Bearish?

November 10, 2018 - By Peter Kolinski

Tesaro, Inc. (NASDAQ:TSRO) LogoInvestors sentiment decreased to 0.93 in Q2 2018. Its down 0.21, from 1.14 in 2018Q1. It worsened, as 59 investors sold Tesaro, Inc. shares while 44 reduced holdings. 29 funds opened positions while 67 raised stakes. 58.58 million shares or 3.28% less from 60.57 million shares in 2018Q1 were reported.
Gp One Trading Limited Partnership owns 64,354 shares. The United Kingdom-based Legal General Grp Plc has invested 0% in Tesaro, Inc. (NASDAQ:TSRO). Moreover, Parametric Port Assoc Limited Co has 0% invested in Tesaro, Inc. (NASDAQ:TSRO). Orbimed Advsr Limited Liability holds 0.04% or 67,281 shares. Ivory Mgmt holds 30,254 shares or 0.27% of its portfolio. Wisconsin-based State Of Wisconsin Board has invested 0% in Tesaro, Inc. (NASDAQ:TSRO). Eulav Asset invested in 0.98% or 480,000 shares. Eventide Asset Management Ltd Liability Company has invested 0.05% in Tesaro, Inc. (NASDAQ:TSRO). Birchview Cap Lp invested in 0.25% or 8,200 shares. Earnest Prtn Limited Liability Company reported 24 shares. Nea Co Ltd Liability Co owns 10.42M shares for 21.71% of their portfolio. America First Investment Advisors Ltd Limited Liability Company has invested 0.01% in Tesaro, Inc. (NASDAQ:TSRO). Teacher Retirement Sys Of Texas invested 0% in Tesaro, Inc. (NASDAQ:TSRO). Northern Tru holds 263,889 shares. Frontier Capital Ltd holds 0.56% of its portfolio in Tesaro, Inc. (NASDAQ:TSRO) for 1.76M shares.

Since June 12, 2018, it had 0 buys, and 2 insider sales for $310,256 activity. The insider Alleva Lawrence M sold 7,142 shares worth $307,920.

Tesaro, Inc. (NASDAQ:TSRO) Ratings Coverage

Among 5 analysts covering Tesaro (NASDAQ:TSRO), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Tesaro had 10 analyst reports since May 31, 2018 according to SRatingsIntel. The rating was upgraded by Barclays Capital to “Buy” on Wednesday, June 27. On Monday, August 6 the stock rating was downgraded by Bank of America to “Neutral”. Citigroup maintained it with “Buy” rating and $85 target in Wednesday, August 29 report. The rating was maintained by Citigroup on Thursday, May 31 with “Buy”. Bank of America maintained it with “Neutral” rating and $38 target in Tuesday, September 11 report. Barclays Capital maintained Tesaro, Inc. (NASDAQ:TSRO) on Monday, August 6 with “Overweight” rating. The firm earned “Neutral” rating on Friday, November 2 by Bank of America. The firm earned “Overweight” rating on Monday, October 22 by Cantor Fitzgerald. Below is a list of Tesaro, Inc. (NASDAQ:TSRO) latest ratings and price target changes.

02/11/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $38 New Target: $39 Maintain
22/10/2018 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Overweight Old Target: $57 New Target: $68 Maintain
01/10/2018 Broker: Cantor Fitzgerald Rating: Overweight New Target: $57 Initiates Coverage On
25/09/2018 Broker: Leerink Swann Rating: Outperform New Target: $48 Initiates Coverage On
11/09/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $35 New Target: $38 Maintain
29/08/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $100 New Target: $85 Maintain
06/08/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $60 New Target: $56 Maintain
06/08/2018 Broker: Bank of America Old Rating: Buy New Rating: Neutral Downgrade
27/06/2018 Broker: Barclays Capital Rating: Buy New Target: $60.0000 Upgrade
31/05/2018 Broker: Citigroup Rating: Buy New Target: $100.0000 Maintain

The stock decreased 18.80% or $5.81 during the last trading session, reaching $25.1. About 3.88M shares traded or 125.64% up from the average. Tesaro, Inc. (NASDAQ:TSRO) has declined 70.32% since November 10, 2017 and is downtrending. It has underperformed by 85.94% the S&P500.

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. The company has market cap of $1.38 billion. It markets Rolapitant, a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting under the VARUBI brand name. It currently has negative earnings. The firm is also developing Niraparib, an orally active and potent poly polymerase inhibitor, which is in various clinical trials to treat ovarian or breast cancers.

More notable recent Tesaro, Inc. (NASDAQ:TSRO) news were published by: Nasdaq.com which released: “Here’s Why AnaptysBio, Inc. Slipped on Friday” on November 09, 2018, also Globenewswire.com with their article: “TESARO Announces Data Presentations at ESMO 2018 Congress” published on October 20, 2018, Seekingalpha.com published: “TESARO Inc’s (TSRO) CEO Lonnie Moulder on Q3 2018 Results – Earnings Call Transcript” on November 02, 2018. More interesting news about Tesaro, Inc. (NASDAQ:TSRO) were released by: Globenewswire.com and their article: “TESARO Announces Third-Quarter 2018 Operating Results” published on November 01, 2018 as well as Fool.com‘s news article titled: “Here’s Why Tesaro Inc. Dropped 13.8% Today” with publication date: October 24, 2018.

Tesaro, Inc. (NASDAQ:TSRO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>